Career history of Joseph Beaulieu
Former positions of Joseph Beaulieu
Companies | Position | Start | End |
---|---|---|---|
EPIZYME, INC. | Comptroller/Controller/Auditor | 2018-06-30 | 2023-01-31 |
Treasurer | 2018-06-30 | - | |
Morningstar, Inc. (Research)
Morningstar, Inc. (Research) Investment ManagersFinance Morningstar, Inc. (Research) is the investment research arm of Morningstar, Inc. (NASDAQ: MORN), an American financial services firm headquartered in Chicago, Illinois. The firm was founded by Joseph Mansueto in 1984 and provides independent portfolio information offering star ratings and analysis of managed funds. They also provide economic commentary and asset allocation information based on qualitative research. | Analyst-Equity | 2009-04-30 | 2011-08-30 |
Director of Research - Equity | 2009-04-30 | 2011-08-30 | |
ABN AMRO Securities (USA), Inc. | Analyst-Equity | 1999-10-30 | 1999-10-30 |
Training of Joseph Beaulieu
The University of Chicago | Undergraduate Degree |
University of Illinois | Graduate Degree |
Wallace E Carroll School of Management | Undergraduate Degree |
Statistics
International
United States | 7 |
Operational
Analyst-Equity | 2 |
Undergraduate Degree | 2 |
Director of Research - Equity | 1 |
Sectoral
Consumer Services | 4 |
Finance | 3 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Morningstar, Inc. (Research)
Morningstar, Inc. (Research) Investment ManagersFinance Morningstar, Inc. (Research) is the investment research arm of Morningstar, Inc. (NASDAQ: MORN), an American financial services firm headquartered in Chicago, Illinois. The firm was founded by Joseph Mansueto in 1984 and provides independent portfolio information offering star ratings and analysis of managed funds. They also provide economic commentary and asset allocation information based on qualitative research. | Finance |
ABN AMRO Securities (USA), Inc. | Finance |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Joseph Beaulieu
- Experience